Suppr超能文献

80 岁及以上患者脑胶质母细胞瘤切除术的结果。

Outcome of glioblastoma resection in patients 80 years of age and older.

机构信息

Pôle Neuroscience (Neurochirurgie), Centre Hospitalo-Universitaires de Toulouse, Université de Toulouse, Toulouse, France.

UPS (Université Paul Sabatier), Toulouse, France.

出版信息

Acta Neurochir (Wien). 2022 Feb;164(2):373-383. doi: 10.1007/s00701-021-04776-5. Epub 2021 Mar 4.

Abstract

OBJECTIVE

To evaluate the role and possible complications of tumor resection in the management of glioblastoma (GBM) in a series of patients 80 years of age and older with review of literature.

METHODS

The authors retrospectively analyzed cases involving patients 80 years or older who underwent biopsy or initial resection of GBM at their hospital between 2007 and 2018. A total of 117 patients (mean age 82 years) met the inclusion criteria; 57 had resection (group A) and 60 had biopsy (group B). Functional outcomes and survival at follow-up were analyzed.

RESULTS

Group A differed significantly from group B at baseline in having better WHO performance status, better ASA scores, more right-sided tumors, and no basal ganglia or "butterfly" gliomas. Nevertheless, 56% of group A patients had an ASA score of 3. Median survival was 9.5 months (95% CI 8-17 months) in group A, 4 months (95% CI 3.5-6 months) in group B, and 17.5 months (95% CI 12-24 months) in the 56% of group A patients treated with resection and Stupp protocol. Rates of postoperative neurologic and medical complications were almost identical in the 2 groups, but the rate of surgical site complications was substantially greater in group A (12% vs 5%). There was no significant difference in mean preoperative and postoperative KPS scores (group A).

CONCLUSIONS

In selected patients 80 years or older, radical removal of GBM was associated with acceptable survival and a low perioperative complication rate which is comparable to that of a biopsy. Although the median survival of the whole group was lower than reported for younger patients, a subgroup amenable to radical surgery and Stupp protocol achieved a median survival of 17.5 months.

摘要

目的

通过文献回顾,评估在一系列 80 岁及以上的患者中,肿瘤切除术在胶质母细胞瘤(GBM)治疗中的作用和可能的并发症。

方法

作者回顾性分析了 2007 年至 2018 年期间在其医院接受 GBM 活检或初始切除的 80 岁及以上患者的病例。共有 117 名患者(平均年龄 82 岁)符合纳入标准;57 例行切除术(A 组),60 例行活检术(B 组)。分析随访时的功能结局和生存情况。

结果

A 组在基线时与 B 组相比,表现出更好的世界卫生组织(WHO)功能状态、美国麻醉医师协会(ASA)评分、更多右侧肿瘤、无基底节或“蝴蝶”胶质瘤。然而,A 组中有 56%的患者 ASA 评分为 3 级。A 组的中位生存期为 9.5 个月(95%CI 8-17 个月),B 组为 4 个月(95%CI 3.5-6 个月),A 组中 56%接受切除和 Stupp 方案治疗的患者的中位生存期为 17.5 个月(95%CI 12-24 个月)。两组术后神经和医疗并发症发生率几乎相同,但 A 组手术部位并发症发生率明显更高(12%比 5%)。A 组患者的平均术前和术后 KPS 评分无显著差异(A 组)。

结论

在选择的 80 岁及以上患者中,GBM 的根治性切除与可接受的生存和较低的围手术期并发症发生率相关,与活检术相当。尽管全组的中位生存期低于报道的年轻患者,但可接受根治性手术和 Stupp 方案的亚组患者的中位生存期为 17.5 个月。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验